Effects of HIV treatment on weight in postpartum women and their infants
Metabolic impact of ART on women living with HIV and their infants
This study is looking at how the HIV medication Dolutegravir affects weight in new moms living with HIV and their babies, comparing them to moms on different treatments and those without HIV, to help find better ways to manage weight and health for these families.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10861861 on NIH RePORTER |
What this research studies
This research investigates how the HIV treatment drug Dolutegravir (DTG) affects weight regulation in postpartum women living with HIV and their infants. It aims to understand the differences in body weight changes between women on DTG and those on other treatments, as well as women without HIV. By conducting a cohort study in Uganda, the research will analyze energy intake, expenditure, and various metabolic factors that influence body weight. The findings could lead to better interventions for managing weight and reducing health risks in this population.
Who could benefit from this research
Good fit: Ideal candidates for this research are postpartum women living with HIV who are on Dolutegravir or other HIV treatment regimens.
Not a fit: Patients who are not postpartum women or those who do not have HIV may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could help develop strategies to manage weight gain and reduce the risk of obesity and related diseases in postpartum women living with HIV.
How similar studies have performed: Previous research has shown that weight gain can occur with certain HIV treatments, but this specific investigation into postpartum women and DTG is relatively novel.
Where this research is happening
New York, United States
- Columbia University Health Sciences — New York, United States (Active)
Researchers
- Principal investigator: Shivakoti, Rupak — Columbia University Health Sciences
- Study coordinator: Shivakoti, Rupak
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.